# A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

> **NCT03941873** · PHASE1,PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 111 (actual)

## Conditions studied

- Carcinoma, Hepatocellular
- Gastric/Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Sitravatinib
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT03941873
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941873, "A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT03941873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*